NBIX vs. TECH, XLRN, QGEN, MNTA, BIIB, ALNY, BMRN, INCY, UTHR, and EXAS
Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Bio-Techne (TECH), Acceleron Pharma (XLRN), Qiagen (QGEN), Momenta Pharmaceuticals (MNTA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Bio-Techne (NASDAQ:TECH) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.
Neurocrine Biosciences has a net margin of 18.65% compared to Neurocrine Biosciences' net margin of 17.59%. Bio-Techne's return on equity of 17.45% beat Neurocrine Biosciences' return on equity.
Bio-Techne currently has a consensus price target of $81.00, suggesting a potential upside of 4.94%. Neurocrine Biosciences has a consensus price target of $150.85, suggesting a potential upside of 11.40%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Bio-Techne has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences received 597 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 4.5% of Bio-Techne shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Bio-Techne has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
In the previous week, Neurocrine Biosciences had 12 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 11 mentions for Bio-Techne. Neurocrine Biosciences' average media sentiment score of 1.00 beat Bio-Techne's score of 0.58 indicating that Bio-Techne is being referred to more favorably in the media.
Summary
Neurocrine Biosciences beats Bio-Techne on 12 of the 19 factors compared between the two stocks.
Get Neurocrine Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Neurocrine Biosciences Competitors List
Related Companies and Tools